Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer - Pipeline Review, H2 2019, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.
Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Esophageal Cancer - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 69, 76, 4, 31 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 4 and 3 molecules, respectively.
Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
Introduction
Esophageal Cancer - Overview
Esophageal Cancer - Therapeutics Development
Esophageal Cancer - Therapeutics Assessment
Esophageal Cancer - Companies Involved in Therapeutics Development
Esophageal Cancer - Drug Profiles
Esophageal Cancer - Dormant Projects
Esophageal Cancer - Discontinued Products
Esophageal Cancer - Product Development Milestones
Appendix
List of Tables
Table 1: Number of Products under Development for Esophageal Cancer, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 8: Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 9: Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Table 10: Number of Products under Development by Universities/Institutes, H2 2019
Table 11: Products under Development by Companies, H2 2019
Table 12: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 13: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 14: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 15: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 16: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 17: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 18: Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Table 19: Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Table 20: Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Table 21: Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Table 22: Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Table 23: Products under Development by Universities/Institutes, H2 2019
Table 24: Number of Products by Stage and Target, H2 2019
Table 25: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 26: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Table 27: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Table 28: Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Table 29: Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019
Table 30: Number of Products by Stage and Mechanism of Action, H2 2019
Table 31: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 32: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Table 33: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Table 34: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Table 35: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019
Table 36: Number of Products by Stage and Route of Administration, H2 2019
Table 37: Number of Products by Stage and Molecule Type, H2 2019
Table 38: Esophageal Cancer - Pipeline by AbbVie Inc, H2 2019
Table 39: Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2019
Table 40: Esophageal Cancer - Pipeline by ADC Therapeutics SA, H2 2019
Table 41: Esophageal Cancer - Pipeline by Aduro BioTech Inc, H2 2019
Table 42: Esophageal Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2019
Table 43: Esophageal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2019
Table 44: Esophageal Cancer - Pipeline by Agios Pharmaceuticals Inc, H2 2019
Table 45: Esophageal Cancer - Pipeline by Ambrx Inc, H2 2019
Table 46: Esophageal Cancer - Pipeline by amcure GmbH, H2 2019
Table 47: Esophageal Cancer - Pipeline by Amgen Inc, H2 2019
Table 48: Esophageal Cancer - Pipeline by AMI Onco Theranostics LLC, H2 2019
Table 49: Esophageal Cancer - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2019
Table 50: Esophageal Cancer - Pipeline by Anhui Kedgene Biotechnology Co Ltd, H2 2019
Table 51: Esophageal Cancer - Pipeline by Apexigen Inc, H2 2019
Table 52: Esophageal Cancer - Pipeline by Apollomics Inc, H2 2019
Table 53: Esophageal Cancer - Pipeline by Aprea Therapeutics AB, H2 2019
Table 54: Esophageal Cancer - Pipeline by Ascenta Therapeutics Inc, H2 2019
Table 55: Esophageal Cancer - Pipeline by Ascentage Pharma Group International, H2 2019
Table 56: Esophageal Cancer - Pipeline by AstraZeneca Plc, H2 2019
Table 57: Esophageal Cancer - Pipeline by AVEO Oncology Inc, H2 2019
Table 58: Esophageal Cancer - Pipeline by Bayer AG, H2 2019
Table 59: Esophageal Cancer - Pipeline by BeiGene Ltd, H2 2019
Table 60: Esophageal Cancer - Pipeline by Bicycle Therapeutics Plc, H2 2019
List of Figures
Figure 1: Number of Products under Development for Esophageal Cancer, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
